It seems evident from the recent success of ceritinib and the fast-track FDA approval of alectinib that genomic profiling of NSCLC tumors is necessary to personalize the treatment of ALK-positive lung cancer patients [65]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.